Targeted Oncology company information, Employees & Contact Information

FDA Approves Revumenib in Mutant NPM1 AML Targeted Oncology

After Setbacks, FDA Approves Belantamab Mafodotin Combo in Myeloma Targeted Oncology

"Transformational" innovaTV Long-Term OS Data for Cervical Cancer Targeted Oncology

Survival Data Strengthens Case for Abemaciclib in High-Risk Breast Cancer Targeted Oncology

Durability, Transfusion Independence Achieved With IDH1 Inhibition in MDS Targeted Oncology

Treating Metastatic DTC After Radioactive Iodine Progression Targeted Oncology

NBTXR3 Well Tolerated in R/M HNSCC, With Early Efficacy Signals Targeted Oncology

Dr Bellmunt Discusses ctDNA Usage for Bladder Cancer in the Community Targeted Oncology

FDA Grants Fast Track to NG-350A for pMMR Rectal Cancer Targeted Oncology

The Targeted Pulse: Updates in Lung, Breast, and Skin Cancers Targeted Oncology

Defining Survival: FDA's New Requirements for Oncology Trial Design Targeted Oncology

Zongertinib Maintains Efficacy Benefit in First-line HER2-Mutated NSCLC CancerNetwork

How NBTXR3 Amplifies Radiotherapy Targeted Oncology

FDA Guidance: Overall Survival as a Safety End Point, Not Just Efficacy Targeted Oncology

FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer Targeted Oncology

Does Project Optimus Apply to Radiopharmaceuticals? Targeted Oncology

Radiopharmaceuticals: Project Optimus, Dose Justification, and Dosimetry Weight Targeted Oncology

FDA Radiopharmaceutical Dosing: Beyond EBRT Limits & Safety Follow-Up Targeted Oncology

The Targeted Pulse: Your Weekly Oncology Wrap-Up Targeted Oncology

Azacitidine, Ruxolitinib Pairing Highlighted in Advanced MPN Targeted Oncology

Xevinapant Fails to Improve EFS in Patients with Head and Neck Cancer Targeted Oncology

Cancer Care in Younger Adults: A Multidisciplinary Team in Practice Targeted Oncology

Zanubrutinib in TN CLL: Expert Insights on Latest Data From SEQUOIA Arm C Targeted Oncology

Orca-T Earns FDA Priority Review in Heme Malignancies Targeted Oncology

Novel Assay Identifies Low-Risk Patients With ER+ Early Breast Cancer Targeted Oncology

FDA Approves Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Events Targeted Oncology

FDA Approval Path Remains Unclear for RP1 in Melanoma Targeted Oncology

Current Physician Treatment Preferences for Frontline Metastatic ccRCC Targeted Oncology

FDA Accepts NDA for Relacorilant in Platinum-Resistant Ovarian Cancer Targeted Oncology

FDA Approves Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer Targeted Oncology

FDA Approves Selumetinib in Patients 1 Year and Older for NF1 with PN Targeted Oncology

PIC Monotherapy Shows Long-Term Promise in Patients with Glioblastoma and HCC Targeted Oncology

Approaching a Critical Juncture to Preserve the Oncology Enterprise Targeted Oncology

Behind the FDA Approval of Dordaviprone, a New Hope for Glioma Targeted Oncology

Biomarker Testing in NSCLC Leads to Renewed Focus on Biopsy Outcomes Targeted Oncology

FDA Approves Intravesical Gemcitabine Delivery for Bladder Cancer Targeted Oncology

Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer Targeted Oncology

FDA Grants Accelerated Approval to Zongertinib in HER2 NSCLC Targeted Oncology

CAR T Deepens Myeloma Response Over Time, Could Overcome High Risk Targeted Oncology

FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Pancreatic Cancer Targeted Oncology

ProMPT Enhances NGS Reports to Delineate Treatment Complexities Targeted Oncology

Expert Perspectives: T-Cell Fitness and Its Role in CAR-T Treatment Planning Targeted Oncology

Targeted Vaccine Leads to Broad Immune Response in Pancreatic Cancer Targeted Oncology

Dr Burke Discusses Daratumumab in Smoldering Myeloma Targeted Oncology

Talquetamab Bridges Myeloma Patients to Safer CAR T-Cell Therapy Targeted Oncology

Zanidatamab’s Unique Bispecific Action in HER2-Positive BTC Targeted Oncology

FDA Grants Priority Review for Lurbinectedin/Atezolizumab in ES-SCLC Targeted Oncology

FDA Grants Priority Review to Sevabertinib in HER2-Mutant NSCLC Targeted Oncology

FDA Greenlights Linvoseltamab in Relapsed/Refractory Multiple Myeloma Targeted Oncology

Exploring Differences in Survival With Lenvatinib in Recent HCC Trials Targeted Oncology

RAMP 201 Data Shows Advancements in Recurrent Low-Grade Serous Ovarian Cancer Targeted Oncology

Carotuximab Shows Promising Safety in Metastatic CRPC Phase 2 Trial Targeted Oncology

Real-World Retrospective Study Confirms Efficacy, Safety of Neoadjuvant ICIs in dMMR/MSI Nonmetastatic Colon Cancer Targeted Oncology

Integrating Novel Agents: Clinical Positioning of Hepcidin Mimetics Targeted Oncology

Selecting Cytotoxic Partner For Pembrolizumab in PD-L1+ TNBC Targeted Oncology

FDA Approves Lurbinectedin/Atezolizumab for ES-SCLC Maintenance Targeted Oncology

Safety and Efficacy of Zanidatamab in BTC Targeted Oncology

Atezolizumab/Chemo Reduces Risk of Recurrence or Death by 50% in dMMR Colon Cancer Targeted Oncology

Design and Clinical Outcomes From the IMFORTE Trial Targeted Oncology

Considering Practice-Changing Maintenance Options in Bladder Cancer Targeted Oncology

Deep Responses and Favorable Safety with Linvoseltamab in HR-SMM Targeted Oncology

Preserving Fertility: Options for Patients With Cancer Targeted Oncology

Dordaviprone Receives Accelerated FDA Approval for Diffuse Midline Glioma Targeted Oncology

Bridging and BCMA Exposure Impact Ide-Cel Outcomes in Multiple Myeloma Targeted Oncology

Across Cancer Types, Trispecific Antibodies Show Promise in Early Result Targeted Oncology

Novel CDK2 Inhibitor INCB123667 Shows Promise in Ovarian Cancer Targeted Oncology

TAR-200 Offers New Hope for BCG-Unresponsive Bladder Cancer Targeted Oncology

Larotrectinib Shows Robust Efficacy and Safety in TRK Fusion Cancer Targeted Oncology

Real-World Evidence Reveals CAR T Sequencing Approach in Myeloma Targeted Oncology

FDA Issues CRL for RP1 in Advanced Melanoma Targeted Oncology

Gemcitabine Intravesical System Changes the Paradigm of Bladder Cancer Treatment Targeted Oncology

Gedatolisib Shows Impressive PFS in HR+/HER2– Breast Cancer Targeted Oncology

FDA Grants Priority Review to NDA of TAR-200 in BCG-Unresponsive NMIBC Targeted Oncology

FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy Targeted Oncology

Osimertinib Plus Chemotherapy Significantly Extends Survival in Advanced EGFRm NSCLC Targeted Oncology

FDA Grants Accelerated Approval to Dato-DXd in Previously Treated EGFR+ NSCLC Targeted Oncology

Immunosuppressive Antibody Discontinued After Patient Death in Lymphoma Trial Targeted Oncology

The Time-Sensitive World of Fertility Preservation for Patients With Cancer Targeted Oncology

FDA Approves SIR-Spheres Y-90 for First-Line Use in Unresectable HCC Targeted Oncology

Cell-Free DNA: Revolutionizing Breast Cancer Management and Screening Targeted Oncology

FDA Grants Fast Track Status to PHST001 in Ovarian Cancer Targeted Oncology

Sacituzumab/Pembrolizumab Combo Shows Promise in Bladder Cancer Targeted Oncology

FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer Targeted Oncology

Gedatolisib Shows Encouraging Early Efficacy in mCRPC and HER2+ mBC Targeted Oncology

Safety of Linvoseltamab in High-Risk Smoldering Myeloma Targeted Oncology

Optimizing R/R DLBCL Treatment: Azer-Cel Shows Sustained Responses Targeted Oncology

PQ203 Receives Regulatory Clearance for Breast Cancer Trial Targeted Oncology

BTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS Targeted Oncology

Sacituzumab Govitecan Shows Antitumor Activity in Metastatic Cervical Cancer Targeted Oncology

Dr Muvner on Targeted Therapies in Prostate Cancer Targeted Oncology

FDA Greenlights Perioperative Pembrolizumab in Resectable HNSCC Targeted Oncology

Patient-Centric Strategy Is Key to Managing Toxicities in Older Patients With Cancer Targeted Oncology

Autologous TIL Cell Therapy: A Potential Next Line of Treatment for HNSCC Targeted Oncology

Phase 1 Trial of mRNA-4106 Begins Dosing Patients With Solid Tumors Targeted Oncology

Novel KRAS G12D Inhibitor Shows Promising Efficacy in Advanced NSCLC Targeted Oncology

BRUIN Trial Establishes Efficacy of Noncovalent BTK in Pretreated CLL Targeted Oncology

SGX301 Shows Rapid and Durable Responses in Early-Stage CTCL Targeted Oncology

FDA Clears IND Application for ST-001 in SCLC Targeted Oncology

FDA Fast-Tracks Novel ADC in Cervical Cancer Targeted Oncology

FDA Approves Zanubrutinib Tablet for All Indications Targeted Oncology